Ticagrelor Increases Platelet-Mediated Staphylococcus aureus Killing, Resulting in Clearance of Bacteremia.
Erlinda R UlloaSatoshi UchiyamaRobert GillespieVictor NizetGeorge SakoulasPublished in: The Journal of infectious diseases (2022)
Platelets are a critical immune defense against Staphylococcus aureus bloodstream infections. Staphylococcus aureus α-toxin is a virulence factor that decreases platelet viability and accelerates platelet clearance. It has been shown that ticagrelor blocks α-toxin-mediated platelet injury and resulting thrombocytopenia, protecting mice in a lethal S. aureus sepsis model. We now present the use of ticagrelor as adjunctive therapy in a patient with a S. aureus endovascular infection and thrombocytopenia, associated with restoration of platelet count and bacteremia clearance. Ticagrelor enhanced platelet killing of the S. aureus bloodstream isolate from the treated patient in vitro.
Keyphrases
- staphylococcus aureus
- acute coronary syndrome
- percutaneous coronary intervention
- escherichia coli
- st segment elevation myocardial infarction
- biofilm formation
- st elevation myocardial infarction
- antiplatelet therapy
- case report
- intensive care unit
- pseudomonas aeruginosa
- gram negative
- methicillin resistant staphylococcus aureus
- type diabetes
- klebsiella pneumoniae
- cystic fibrosis
- mesenchymal stem cells
- multidrug resistant
- candida albicans
- bone marrow
- peripheral blood
- replacement therapy